SGLT2抑制剂和GLP-1受体激动剂对2型糖尿病患者心血管保护作用研究进展  

Research progress of cardiovascular protective effect of SGLT2 inhibitors and GLP-1 receptor agonists on patients with type 2 diabetes mellitus

作　　者：郭凌波 王昱[1] GUO Ling-bo;WANG Yu(Department of General Medicine,Central Hospital of Nanyang City,Nanyang,He′nan,473000,China)

机构地区：[1]南阳市中心医院全科医疗科,河南南阳473000

出　　处：《心血管康复医学杂志》2023年第3期290-294,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：大量研究表明钠-葡萄糖共转运体2(SGLT2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(GLP-1RA)在降低2型糖尿病(T2DM)患者的死亡率和心血管风险方面显示出积极的效果。本文综述了SGLT2抑制剂和GLP-1RA对T2DM患者心血管获益有关的临床研究。以期针对T2DM合并心血管疾病患者的不同临床受益情况,提供个体化用药选择思路。Numerous studies suggest that sodium-glucose co-transporter 2(SGLT2)inhibitors and glucagon-like peptide 1(GLP-1)receptor agonists(GLP-1RA)have shown positive effects in reducing mortality and cardiovascular risk in patients with type 2 diabetes mellitus(T2DM).The present article reviews clinical studies on the cardiovascular benefits of SGLT2 inhibitors and GLP-1RA in T2DM patients in order to provide thinking of individual drug selection for the different clinical benefits in T2DM patients with cardiovascular diseases.

关 键 词：心血管疾病 糖尿病 2型 钠-葡萄糖转运体2 受体 胰高血糖素 

分 类 号：R54[医药卫生—心血管疾病]